U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393438) titled 'Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)' on Jan. 19.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB).
The primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the recommended phase II dose (RP2D) of AHA.
The secondary objectives include evaluating th...